X-Linked Retinitis Pigmentosa
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Have RPGR-associated retinal dystrophy - Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate - Are able to undertake age-appropriate clinical assessments as specified in the protocol
Exclusion criteria
Exclusion criteria: - Are unable or unwilling to undertake consent or clinical testing - Participated in another research study and had intraocular surgery within 3 months of screening - Significant ophthalmologic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Function Up to Day 30 Visual function will be assessed using visual acuity. Retinal Structure Up to Day 30 Retinal structure will be assessed using spectral domain optical coherence tomography (SDOCT). Retinal Function Up to Day 30 Retinal function will be assessed using static visual field testing. | — |
Countries
Japan
Contacts
Janssen Pharmaceutical K.K. Medical Information Center